ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Peptidream, Inc.

Business Summary

PeptiDream, Inc. engages in the biopharmaceutical business that includes research and development of non-standard peptide therapeutics. It produces macrocyclic peptides based on its proprietary Peptide Discovery Platform System (PDPS). The company was founded by Kiichi Kubota and Hiroaki Suga on July 3, 2006 and is headquartered in Kawasaki, Japan.

Financial Highlights

Dec 2021 JPYUSD
Revenue9,365.96M85.24M
Gross Profit6,937.89M63.14M
Operating income4,418.14M40.21M
Income before tax4,823.65M43.90M
Net income3,606.40M32.82M
EBITDA5,051.15M45.97M
Diluted EPS27.770.25
Dividends Per Share00
Total Assets26,619.16M231.15M
Total liabilities1,620.57M14.07M
Total equity24,998.59M217.08M
Operating cash flow6,654.70M60.56M
Currency in JPYCurrency in USD

Historical Data

 Jun 2017Jun 2018Dec 2019Dec 2020Dec 2021
Revenue 4,895.74M 6,426.89M 2,074.67M 11,677.25M 9,365.96M
Gross Profit 3,530.02M 4,648.26M 661.06M 9,459.96M 6,937.89M
Operating income 2,490.41M 2,978.48M -1,774.33M 6,991.32M 4,418.14M
Income before tax 2,624.15M 3,151.73M -1,413.07M 6,020.02M 4,823.65M
Net income 1,890.75M 2,335.21M -976.92M 4,448.35M 3,606.40M
EBITDA 2,685.28M 3,491.82M -1,261.79M 7,562.34M 5,051.15M
Diluted EPS 14.56 17.79 -7.80 34.26 27.77
Dividends Per Share 0 0 0 0 0
Total Assets 13,628.45M 16,512.83M 17,817.34M 26,266.72M 26,619.16M
Total liabilities 1,447.65M 1,804.11M 839.05M 5,049.72M 1,620.57M
Total equity 12,180.80M 14,708.71M 16,978.28M 21,217.00M 24,998.59M
Operating cash flow 1,530.77M 1,022.71M 241.98M 1,732.73M 6,654.70M
 Jun 2017Jun 2018Dec 2019Dec 2020Dec 2021
Revenue 44.87M 58.24M 19.03M 109.36M 85.24M
Gross Profit 32.35M 42.12M 6.06M 88.60M 63.14M
Operating income 22.82M 26.99M -16.27M 65.48M 40.21M
Income before tax 24.05M 28.56M -12.96M 56.38M 43.90M
Net income 17.33M 21.16M -8.96M 41.66M 32.82M
EBITDA 24.61M 31.64M -11.57M 70.82M 45.97M
Diluted EPS 0.13 0.16 -0.07 0.32 0.25
Dividends Per Share 0 0 0 0 0
Total Assets 121.29M 149.07M 163.95M 254.41M 231.15M
Total liabilities 12.88M 16.28M 7.72M 48.91M 14.07M
Total equity 108.40M 132.79M 156.22M 205.50M 217.08M
Operating cash flow 14.03M 9.26M 2.21M 16.22M 60.56M

Valuation Measures

Dec 2021
PER90.96
ROA13.63%
ROE15.60%
Operating margin47.17%
Profit margin38.50%

Key executives

  • President, CEO & Representative Director: Patrick Crawford Reid
  • Chief Operating Officer, Director & Vice President: Keiichi Masuya
  • Chief Financial Officer, Director & Vice President: Kiyofumi Kaneshiro
  • Director-Public Relations & Investor Relations: Yuko Okimoto

Shareholders

  • KUBOTA KIICHI (10.4%)
  • SUGA HIROAKI (9.3%)
  • Taiyo Pacific Partners LP (7.2%)
  • JOHCM (Singapore) Pte Ltd. (4.4%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.6%)
  • REID PATRICK C (3.4%)
  • MURAKAMI HIROSHI /PEPTIDREAM INC/ (3.3%)
  • Invesco Advisers, Inc. (2.3%)
  • Baillie Gifford & Co. (2.3%)
  • Nomura Asset Management Co., Ltd. (2.2%)

Contact Details

Related Companies

  • PeptiAID, Inc.
  • Fujifilm Toyama Chemical /Radiopharmaceutical Bus/
  • Peptidream Board Incentive Plan
  • Peptidream Employee Incentive Plan
  • PharmaDesign, Inc. (Japan) /Pharma Research Bus/
  • PharmaDesign, Inc. (Japan)

Competitors

  • Aileron Therapeutics, Inc.
  • Apellis Pharmaceuticals, Inc.
  • Bicycle Therapeutics Plc Sponsored ADR
  • Protagonist Therapeutics, Inc.
  • UCB S.A.
  • Avidity Biosciences Inc
Last Updated on 26 Sep, 2022

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more